Research programme: adoptive cell therapeutics - Immatics

Drug Profile

Research programme: adoptive cell therapeutics - Immatics

Alternative Names: IMA 102; IMA 201; IMA 202; IMA 203; IMA 300; IMA 301

Latest Information Update: 15 Oct 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Immatics US
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 17 Aug 2017 Immatics plans a phase I trial of IMA 201 for Solid tumours (Late-stage disease) in USA (NCT03247309)
  • 30 Sep 2015 Preclinical trials in Cancer in USA (unspecified route) before September 2015
  • 26 Aug 2015 Immatics and The University of Texas MD Anderson cancer centre announced the launch of Immatics US to develop adoptive cell-based therapeutics for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top